What does Upadacitinib treat?

Upadacitinib (Upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and nonradiographic axial spondyloarthritis. Upadatinib, available as an extended-release tablet that may be taken by mouth once daily, works by blocking the activity of Janus kinase in the JAK-STAT signaling pathway, an intracellular pathway that plays a major role in the release of pro-inflammatory cytokines that stimulate inflammation in rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis and nonradiographic axial spondyloarthritis.